20 RESULTS
Go to another page:
COMMENT The recent reports from the Aguzzi/Budka and Collinge/Brandner laboratories reminded me that we were possibly the first to describe Aβ deposition in iatrogenic CJD, in 1989 and 1996 in a 56-year-old man (Simpson et al., 1996). We thought that the ...
COMMENT These results of the Aβ CSF kinetics on 112 subjects are a major advance in quantification of the deposition and accumulation of Aβ in the AD brain. The increase in half-life from 3.8 hours to 9.4 hours over a 50-year time span is exactly the information ...
COMMENT The IMAGINE study conducted by Prana Biotechnology was a small (n=42) exploratory trial supported by a grant from the Alzheimer’s Drug Discovery Foundation to see if the novel 8-OH quinoline (PBT2) would have an effect on Aβ-amyloid burden as reported by ...
COMMENT Sanjay Pimplikar is a regular commentator on Alzforum. In the current comments, I think the view promoted is too pessimistic. Although we are already in a dire predicament today because there are no effective therapies for AD, there is considerable hope ...
COMMENT This commentary is very germane. A few major issues deserve further elaboration. Testing the Aβ theory of AD (rather than the “amyloid hypothesis”) still has not been accomplished. The challenges are formidable. While the “right” target may not have been ...
Go to another page:
